Online inquiry

IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4506MR)

This product GTTS-WQ4506MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CXCL10 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001565.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3627
UniProt ID P02778
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4506MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4051MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ4621MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ10778MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-70
GTTS-WQ14249MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ388MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 20D7S
GTTS-WQ13177MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ1736MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ5122MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Campath-1H
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW